VetStem Biopharma products

VetStem Regenerative Cells – Key Safety Factors: Autologous (from the patient back to the same patient): Tissue reaction risk is minimized. Minimally manipulated: Cells are not differentiated or modified. Accurate determination of each dose. Quality assessment of each dose. VetStem employs stringent processing protocols and quality control methods. Hundreds of publications support the safety of autologous cell therapy in animals. Reported canine adverse reaction rate is 0.1%. Reported equine adverse reaction rate is 0.2%. Reported feline adverse reaction rate is 0.3%.

The principle is to accelerate lagging internal healing processes by amplifying the biological signals that would naturally occur when platelets aggregate at a site of injury. By concentrating platelets and releasing more of those growth factors than would naturally occur – the intended effect is to attract stem cells and stimulate local tissue repair processes.

The StemInsure® process can be performed before your dog has arthritis or an injury so that when your dog needs stem cells, no additional fat collection surgery is required.

VetStem is currently evaluating the use of stem cells for treatment in: Laminitis, Uveitis, Exercise Induced Pulmonary Hemorrhage (EIPH).